Active ingredient: Arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine (Arginil-alfa-aspartil-lysil-valil-tyrosil-arginine) Active ingredient concentration (mg): 50 mcg
The drug has immunoregulatory, detoxification, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. Pharmacological action is based on the achievement of 3 main effects: correction of the immune system, restoring the balance of the oxidative-antioxidant reaction of the body and inhibition of multidrug resistance mediated by proteins of the transmembrane cell transport pump. The effect of the drug starts to develop within 2-3 hours 4 months (medium and slow phases). During the fast phase (duration - up to 2-3 days), first of all, the detoxification effect is manifested - it strengthens I antioxidant protecting the body by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol and production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces transaminase activity and serum bilirubin level. During the middle phase (starts after 2-3 days, duration - up to 7-10 days), phagocytosis and death of intracellular bacteria and viruses increase During the slow phase (it begins to develop at 7-10 days, duration up to 4 months), the immunoregulatory effect of the drug is manifested - restoration of impaired indicators of cellular and humoral immunity. During this period, recovery of the immunoregulatory index is observed, an increase in the production of specific antibodies is noted. The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reagin antibodies of the IgE class and does not enhance the reaction of hypersensitivity of the immediate type.Imunofan stimulates the formation of IgA in its congenital insufficiency. Imunofan effectively suppresses the multidrug resistance of tumor cells and increases their sensitivity to the action of chemotherapeutic drugs.
Data on the pharmacokinetics of the drug is not provided.
Used in adults and children older than 2 years for the prevention and treatment of immunodeficiency and toxic conditions, acute and chronic infectious and inflammatory diseases.
Hypersensitivity, children up to 2 years.
Do not exceed recommended doses.
Use during pregnancy and lactation
Due to insufficient knowledge, caution should be used during pregnancy and lactation.
Dosage and administration
Intranasal. When using the bottle should be held vertically, spray up. Remove the protective cap from the sprayer. Before the first use, fill the dosing pump by pressing the wide rim of the sprayer 3-4 times. Insert the nebulizer into the nasal passage with the head upright. Press the wide rim of the spray gun once to stop. A single dose of the drug contains 50 mcg of imunofan. The daily dose should not exceed 200 mg.
Individual intolerance is possible.
Cases of overdose are not described.
Interaction with other drugs
Increases the effectiveness of other types of drug therapy: the use of Imunofan helps to overcome resistance to GCS therapy. Appointment of imunofan possible in combination with the SCS and NSAIDs.
As a result of the activation of phagocytosis, a short-term exacerbation of the foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.